S-CitAD - Escitalopram for Agitation in Alzheimer's DiseaseResearch Question:
Will the antidepressant medicine, escitalopram, help people who have Alzheimer's disease
(AD) with agitation?
Basic Study Information
Purpose:Location: AD-CARE - located at Monroe Community Hospital, 435 East Henrietta Rd., Rochester,
Individuals with a diagnosis of Alzheimer's disease and clinically significant agitation/aggression
as assessed by the Neuropsychiatric Inventory (NPI), and not residing in a skilled
nursing or long-term acute care facility may be eligible to participate. Enrolled
participants will receive 3 weeks of psychosocial intervention (counseling). Those
responding to counseling will be monitored on usual care. Those not responding to
3 weeks of counseling will randomly be assigned to receive daily escitalopram or placebo
(a pill with no active ingredients) while continuing to receive counseling. These
2 groups will be compared to the group responding to counseling alone.
Study Reference #: 70324
Lead Researcher (Principal Investigator)
Lead Researcher: Anton Porsteinsson
Study Contact InformationStudy Coordinator: Susan Salem-Spencer, RN, MSN
Phone: (585) 760-6550
Additional Study Details
The study will last about 6 months. This will include 6 clinic visits for the first
4 months and 7 scheduled telephone calls spread throughout the study. You will be
asked questions about your health, behavior, and memory; blood samples will be taken;
and you will be asked to take simple paper and pencil tests of memory and thinking.
Your caregiver will be asked questions about your health and memory. Counseling will
be provided for both you and your caregiver to help understand and manage your agitation
and Alzheimer's disease.
Number of Visits:
6 to 10
Learn More About These Conditions
More information about Alzheimer's disease
Trial Not Found
The study you are looking for is not active at this time.
Return to Search